Resolution of ANDA 220147 Patent Dispute and Background

The patent litigation between Alkem Laboratories Ltd. (ALKEM.NS) and Otsuka Pharmaceutical Co., Ltd. (4578.T) concerning the generic version of Tolvaptan has been officially concluded through a mutual agreement. This resolution involves the voluntary dismissal (Stipulated Dismissal) of the patent infringement lawsuit (Case No. 1:25-cv-00318) filed in the U.S. District Court for the District of Delaware. Otsuka had initiated the lawsuit, alleging that Alkem intended to prematurely launch a generic version of Tolvaptan, the active ingredient in the branded drug Jynarque, before the expiration of the patent. With the agreement to settle the lawsuit, Alkem's pathway to enter the generic market is now clearly defined.

Market Positioning and Differentiation of Tolvaptan Generic

Tolvaptan, a selective vasopressin V2-receptor antagonist, is the only FDA-approved drug for slowing the progression of kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD). Alkem's ANDA 220147 is a bioequivalence application for a generic version covering all strengths of Jynarque, including 15mg, 30mg, 45mg, 60mg, and 90mg. Alkem has already entered the hyponatremia market with the approval of its generic version of low-dose Samsca (ANDA 211891). However, this agreement differentiates itself by paving the way for Alkem to penetrate the market for the higher-dose Jynarque indication.

Market Size and Projected Impact on Otsuka's Revenue

The global Tolvaptan market is estimated to be approximately $1.62 billion to $2.51 billion in 2024-2025 and is expected to grow at a compound annual growth rate of 5.7% to 8.5% through 2035, making it a high-value market. Otsuka Pharmaceutical's Jynarque franchise has generated global revenue of over 181.5 billion yen (approximately $1.2 billion) as of the third quarter of 2025. However, it has experienced a 13.9% year-on-year decline in revenue due to generic erosion. Therefore, the launch of Alkem's generic product is expected to accelerate the restructuring of market share and erode Otsuka's high-margin monopoly.

Improved Patient Access and Future Regulatory Challenges

The availability of generic drugs can provide a more affordable treatment option for patients with polycystic kidney disease who face the high cost of branded drugs. However, Tolvaptan carries a risk of serious drug-induced liver injury, and its use requires adherence to the FDA's strict risk evaluation and mitigation strategy (REMS) program. Therefore, Alkem faces the regulatory challenge of demonstrating a specialized safety management system for the distribution and monitoring of the drug. With the resolution of the patent litigation, the legal hurdle for final approval has been removed, and the establishment of prescription and distribution infrastructure will be key to commercial success.